Mycophenolate Mofetil
Brand names: Cellcept, Mycophenolate Mofetil
At a glance
- Medicare prescriptions, 2024
- 368,314
- Medicare drug cost
- $45.4M
- Average cost per prescription
- $123
- Clinicians who prescribed it
- 12,441
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
CELLCEPT [mycophenolate mofetil (MMF)] is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning. Increased risk of development of lymphoma and other malignancies, particularly of the skin. Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalizations and fatal outcomes.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Rheumatology 30.7%
- Nurse Practitioners 11.3%
- Neurology 10.4%
- Pulmonology 9.8%
- Nephrology (Kidney) 6.1%
- Dermatology 5.0%
- Internal Medicine 4.7%
- Physician Assistants 4.4%
- Gastroenterology 3.6%
- Hepatology 3.2%
- Heart Failure & Transplant Cardiology 2.2%
- Family Medicine 1.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 28% from 2019 to 2024.
Biggest change by state since 2019
- Louisiana +56%
- Kentucky +53%
- Alabama +46%
- Texas +38%
- Missouri +37%
- Arizona (smallest change) +11%
- Massachusetts (smallest change) +14%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
American Health PAckaging
| Strength | Looks like | Imprint |
|---|---|---|
| 250 mg | blue capsule, 19 mm | 266 |
Camber Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | purple capsule, 18 mm | M12 H |
Genentech, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 250 mg | brown capsule, 19 mm | CELLCEPT 250 ROCHE |
| 500 mg | purple oval tablet, 18 mm | CELLCEPT 500 ROCHE |
Sandoz Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 250 mg | white capsule, 19 mm | 655 |
| 500 mg | purple round tablet, 18 mm | SZ 327 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $47,832 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Genentech, Inc. $29,020
- Chugai Pharmaceutical Co., LTD. $10,042
- Amneal Pharmaceuticals LLC $5,967
- Hikma Pharmaceuticals USA $2,612
- Sandoz Inc. $191
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Aug 2026 · Mylan Pharmaceuticals Inc · Class II
Failed Dissolution Specifications - Jul 2026 · Mylan Pharmaceuticals Inc · Class II
Presence of precipitate
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.